Who are Decitabine/Cedazuridine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Azacitidine Injection, Azacitidine (AZA), decitabine injection, Azacytidine, HAG Regimen, 5-Azacytidin, Dacogen (decitabine) only.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/decitabine-cedazuridine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Decitabine/Cedazuridine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Decitabine/Cedazuridine (Decitabine/Cedazuridine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DNA methyltransferase inhibitor; hypomethylating agent. Area: Oncology.

phase 3 DNA methyltransferase inhibitor; hypomethylating agent DNA methyltransferase (DNMT) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Decitabine/Cedazuridine (Decitabine/Cedazuridine) — Astex Pharmaceuticals, Inc.. Decitabine is a DNA methyltransferase inhibitor that causes hypomethylation of DNA, leading to reactivation of silenced tumor suppressor genes and differentiation of myelodysplastic cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Decitabine/Cedazuridine TARGET	Decitabine/Cedazuridine	Astex Pharmaceuticals, Inc.	phase 3	DNA methyltransferase inhibitor; hypomethylating agent	DNA methyltransferase (DNMT)
Azacitidine Injection	Azacitidine Injection	Ascentage Pharma Group Inc.	marketed	DNA methyltransferase inhibitor	DNA methyltransferase (DNMT)
Azacitidine (AZA)	Azacitidine (AZA)	Memorial Sloan Kettering Cancer Center	marketed	DNA methyltransferase inhibitor	DNA methyltransferase (DNMT)
decitabine injection	decitabine injection	Janssen Korea, Ltd., Korea	marketed	DNA methyltransferase inhibitor	DNA methyltransferase (DNMT)
Azacytidine, HAG Regimen	Azacytidine, HAG Regimen	Shenzhen Second People's Hospital	marketed	DNA methyltransferase inhibitor	DNA methyltransferase (DNMT)
5-Azacytidin	5-Azacytidin	Technische Universität Dresden	phase 3	DNA methyltransferase inhibitor	DNA methyltransferase (DNMT)
Dacogen (decitabine) only	Dacogen (decitabine) only	Eisai Inc.	phase 3	DNA methyltransferase inhibitor	DNA methyltransferase (DNMT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DNA methyltransferase inhibitor; hypomethylating agent class)

Astex Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Decitabine/Cedazuridine — Competitive Intelligence Brief. https://druglandscape.com/ci/decitabine-cedazuridine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing